These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10493949)

  • 81.
    Chauhan S; Samanta S; Sharma N; Thakur JK; Dev K; Sourirajan A
    Heliyon; 2019 Dec; 5(12):e03050. PubMed ID: 32382667
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Generation of an inducible system to express polo-like kinase, Cdc5 as TAP fusion protein during meiosis in Saccharomyces cerevisiae.
    Vaid R; Dev K; Lichten M; Sourirajan A
    3 Biotech; 2016 Dec; 6(2):185. PubMed ID: 28330257
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy.
    Bravo MJ; Burgos-Molina AM; García-Aranda M; Redondo M; Téllez T
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067203
    [TBL] [Abstract][Full Text] [Related]  

  • 84. CEBP-β and PLK1 as Potential Mediators of the Breast Cancer/Obesity Crosstalk: In Vitro and In Silico Analyses.
    Accattatis FM; Caruso A; Carleo A; Del Console P; Gelsomino L; Bonofiglio D; Giordano C; Barone I; Andò S; Bianchi L; Catalano S
    Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447165
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
    Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
    [TBL] [Abstract][Full Text] [Related]  

  • 86. ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner.
    Li P; Shi Y; Gao D; Xu H; Zou Y; Wang Z; Li W
    Int J Biol Sci; 2022; 18(16):6145-6162. PubMed ID: 36439881
    [No Abstract]   [Full Text] [Related]  

  • 87. Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis.
    Kim CH; Kim DE; Kim DH; Min GH; Park JW; Kim YB; Sung CK; Yim H
    Exp Mol Med; 2022 Apr; 54(4):414-425. PubMed ID: 35379935
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cytotoxicity and molecular docking analysis of racemolactone I, a new sesquiterpene lactone isolated from
    Alam P; Tyagi R; Farah MA; Rehman MT; Hussain A; AlAjmi MF; Siddiqui NA; Al-Anazi KM; Amin S; Mujeeb M; Mir SR
    Pharm Biol; 2021 Dec; 59(1):941-952. PubMed ID: 35294328
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Keep Calm and Carry on with Extra Centrosomes.
    Kalkan BM; Ozcan SC; Quintyne NJ; Reed SL; Acilan C
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053604
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification.
    Zhang Y; Ma X; Li H; Zhuang J; Feng F; Liu L; Liu C; Sun C
    Front Pharmacol; 2021; 12():685773. PubMed ID: 34858165
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
    Kressin M; Fietz D; Becker S; Strebhardt K
    Cells; 2021 May; 10(5):. PubMed ID: 34065956
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.
    Baxter M; Chapagai D; Craig S; Hurtado C; Varghese J; Nurmemmedov E; Wyatt MD; McInnes C
    ChemMedChem; 2020 Jun; 15(12):1058-1066. PubMed ID: 32232973
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.
    Moison C; Lavallée VP; Thiollier C; Lehnertz B; Boivin I; Mayotte N; Gareau Y; Fréchette M; Blouin-Chagnon V; Corneau S; Lavallée S; Lemieux S; Marinier A; Hébert J; Sauvageau G
    Blood Adv; 2019 Feb; 3(4):552-563. PubMed ID: 30782614
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition.
    Song R; Hou G; Yang J; Yuan J; Wang C; Chai T; Liu Z
    Oncol Lett; 2018 Nov; 16(5):5739-5744. PubMed ID: 30405751
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Analysis of differential gene expression profile identifies novel biomarkers for breast cancer.
    Pan Y; Liu G; Yuan Y; Zhao J; Yang Y; Li Y
    Oncotarget; 2017 Dec; 8(70):114613-114625. PubMed ID: 29383106
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis.
    Fu Z; Wen D
    Cancers (Basel); 2017 Sep; 9(10):. PubMed ID: 28953239
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Gutteridge RE; Singh CK; Ndiaye MA; Ahmad N
    Cancer Lett; 2017 May; 394():13-21. PubMed ID: 28235541
    [TBL] [Abstract][Full Text] [Related]  

  • 99. PLK1, A Potential Target for Cancer Therapy.
    Liu Z; Sun Q; Wang X
    Transl Oncol; 2017 Feb; 10(1):22-32. PubMed ID: 27888710
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
    Gutteridge RE; Ndiaye MA; Liu X; Ahmad N
    Mol Cancer Ther; 2016 Jul; 15(7):1427-35. PubMed ID: 27330107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.